Literature DB >> 31873820

Intracellular calcium signaling and phospho-antigen measurements reveal functional proximal TCR activation in lymphocytes from septic shock patients.

Charles de Roquetaillade1,2, Khalil Kandara1,3, Morgane Gossez1,3, Estelle Peronnet1,4, Céline Monard5, Martin Cour6, Thomas Rimmelé1,5, Laurent Argaud6, Guillaume Monneret7,8, Fabienne Venet1,3.   

Abstract

Entities:  

Year:  2019        PMID: 31873820      PMCID: PMC6928172          DOI: 10.1186/s40635-019-0287-5

Source DB:  PubMed          Journal:  Intensive Care Med Exp        ISSN: 2197-425X


× No keyword cloud information.
To the editor, Sepsis deeply perturbs immune homeostasis by inducing a complex immune response that varies over time and associates a tremendous systemic inflammatory response to anti-inflammatory mechanisms. As a delayed consequence, some septic patients enter a state of profound immunosuppression [1]. As the latter may persist for weeks, leaving the patient at increased risk of secondary infections, immunostimulation recently appeared as a reasonable therapeutic option in patients with signs of persistent and severe immunosuppression [2]. Septic patients develop marked T lymphocyte dysfunctions such as profound lymphopenia, increased expression of inhibitory co-receptor molecules, decreased repertoire diversity, and reduced functionality (proliferation and cytokine production). These alterations have been repeatedly associated with deleterious outcomes [1, 2]. However, mechanisms leading to these alterations are only partially understood. For instance, while the role of deactivated mTORC1 is established [3], the intrinsic capacity of T cell receptor (TCR) to be activated and to transduce intracellular signalling remains unexplored. Among determinants of T cell response, immediate calcium signaling following TCR ligation is of paramount importance and serves crucial effector functions. Thus, we developed a flow cytometry protocol to follow calcium flux after TCR stimulation in patientsCD4+ T lymphocytes. In addition, phosphorylation of molecules from the proximal and downstream TCR signaling cascade was analyzed (Additional file 1). We included patients with septic shock (according to SEPSIS-3 definition) presenting with features of immunosuppression, i.e., decreased monocyte HLA-DR and lymphocyte count (clinical and immunological characteristics in Additional file 1: Table S1). We show that immediate signaling downstream TCR stimulation was not altered in circulating CD4 lymphocytes from septic shock patients. Indeed, cells exhibited no deregulation of intracytoplasmic calcium influx after TCR ligation compared with healthy controls (OKT3 response, Fig. 1). In agreement, we observed a significant CD3ζ phosphorylation (one of the first molecules to be phosphorylated after TCR engagement) after T cell stimulation in both cells from septic patients and controls (Fig. 2). This showed that immediate response after TCR activation was unaffected after sepsis.
Fig. 1

Intracellular calcium signaling in CD4+ T cells from septic patients and controls upon TCR ligation. Peripheral blood mononuclear cells (PBMC) were isolated from patients and controls and loaded with Fluo-4AM for 30 min at 37 °C. Cells were analyzed by flow cytometry for 5 min at baseline then stimulated by biotinylated anti-CD3 (OKT3) antibody during 90 s before addition of streptavidin to induced TCR stimulation and analyzed for another 5 min. As a positive control, ionomycin was added at the end of experiment. Left, representative example of overtime intracellular calcium staining in one healthy volunteer. Right, intracellular calcium staining following TCR ligation in septic patients (n = 7) and healthy volunteers (controls, age-matched, n = 7) before (baseline), after TCR stimulation (biotinylated anti-CD3 antibodies + streptavidin) and after ionomycin addition. MFI of Fluo-4AM was measured in CD4+ T lymphocytes on 3 periods of 100 s at baseline and after complete TCR stimulation. For each stimulation condition, the maximum MFI was considered. Data are represented as means +/− SD. *p < 0.05 compared to baseline, Wilcoxon paired test

Fig. 2

PI3/Akt/mTOR pathway activation in CD4+ T cells from septic patients and controls upon TCR ligation. PBMCs were isolated from septic patients and controls, stimulated for 7 min with anti-CD2-CD3-CD28 Ab-coated beads (bead/cell ratio = 3/1) and stained with anti-CD4 and anti-CD3z, anti-pS6, anti-pAkt, anti-pERk, and anti-pAMPK antibodies protein phosphorylation was assessed by flow cytometry. Data represent the percentage of positive cells based on FMO staining and as individual values and means +/− SD in 9 septic patients and 9 healthy volunteers (controls) before (baseline, BL) and after TCR stimulation (TCR stim). *p < 0.05 (Wilcoxon paired test, baseline vs TCR stim), #p < 0.05 (Mann-Whitney, healthy volunteers vs patients after stimulation)

Intracellular calcium signaling in CD4+ T cells from septic patients and controls upon TCR ligation. Peripheral blood mononuclear cells (PBMC) were isolated from patients and controls and loaded with Fluo-4AM for 30 min at 37 °C. Cells were analyzed by flow cytometry for 5 min at baseline then stimulated by biotinylated anti-CD3 (OKT3) antibody during 90 s before addition of streptavidin to induced TCR stimulation and analyzed for another 5 min. As a positive control, ionomycin was added at the end of experiment. Left, representative example of overtime intracellular calcium staining in one healthy volunteer. Right, intracellular calcium staining following TCR ligation in septic patients (n = 7) and healthy volunteers (controls, age-matched, n = 7) before (baseline), after TCR stimulation (biotinylated anti-CD3 antibodies + streptavidin) and after ionomycin addition. MFI of Fluo-4AM was measured in CD4+ T lymphocytes on 3 periods of 100 s at baseline and after complete TCR stimulation. For each stimulation condition, the maximum MFI was considered. Data are represented as means +/− SD. *p < 0.05 compared to baseline, Wilcoxon paired test PI3/Akt/mTOR pathway activation in CD4+ T cells from septic patients and controls upon TCR ligation. PBMCs were isolated from septic patients and controls, stimulated for 7 min with anti-CD2-CD3-CD28 Ab-coated beads (bead/cell ratio = 3/1) and stained with anti-CD4 and anti-CD3z, anti-pS6, anti-pAkt, anti-pERk, and anti-pAMPK antibodies protein phosphorylation was assessed by flow cytometry. Data represent the percentage of positive cells based on FMO staining and as individual values and means +/− SD in 9 septic patients and 9 healthy volunteers (controls) before (baseline, BL) and after TCR stimulation (TCR stim). *p < 0.05 (Wilcoxon paired test, baseline vs TCR stim), #p < 0.05 (Mann-Whitney, healthy volunteers vs patients after stimulation) In contrast, activation of more distal molecules in the TCR signaling cascade was impacted. For example, stimulation-induced rise of pAkt and pERK was affected leading to a limited mTORC1 activation capacity as measured by S6 phosphorylation after stimulation. In contrast, activation of AMPK, an inhibitor of mTORC1 was mostly unaltered in patients compared to controls (Fig. 2). In conclusion, the present results obtained in septic shock patients show that proximal TCR signaling remains functional in circulating CD4+ T cells from septic shock patients while downstream activation of mTORC1 pathway is markedly diminished. PI3K-Akt pathway integrates signals from both co-activating/inhibitory receptors and an increased expression of such co-inhibitory receptors has been described on circulating T cells from septic patients [4]. In that respect, this suggests that inhibitory receptors known to block downstream signaling are likely of utmost importance in sepsis-induced T lymphocyte dysfunctions. As TCR from septic lymphocytes remains actionable [5], the present results reinforce the rational for blocking co-inhibitors (e.g., with anti-PD-1) or stimulating mTORC1 (for example with rhIL-7) as reasonable immunoadjuvant approaches to tackle sepsis-induced immunosuppression [6-8]. Additional file 1: Table S1. Clinical and biological data from septic shock patients.
  8 in total

1.  Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559).

Authors:  Richard S Hotchkiss; Elizabeth Colston; Sachin Yende; Derek C Angus; Lyle L Moldawer; Elliott D Crouser; Greg S Martin; Craig M Coopersmith; Scott Brakenridge; Florian B Mayr; Pauline K Park; June Ye; Ian M Catlett; Ihab G Girgis; Dennis M Grasela
Journal:  Crit Care Med       Date:  2019-05       Impact factor: 7.598

2.  Nivolumab plus interferon-γ in the treatment of intractable mucormycosis.

Authors:  David Grimaldi; Olivier Pradier; Richard S Hotchkiss; Jean-Louis Vincent
Journal:  Lancet Infect Dis       Date:  2017-01       Impact factor: 25.071

3.  Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial.

Authors:  Bruno Francois; Robin Jeannet; Thomas Daix; Andrew H Walton; Matthew S Shotwell; Jacqueline Unsinger; Guillaume Monneret; Thomas Rimmelé; Teresa Blood; Michel Morre; Anne Gregoire; Gail A Mayo; Jane Blood; Scott K Durum; Edward R Sherwood; Richard S Hotchkiss
Journal:  JCI Insight       Date:  2018-03-08

Review 4.  Advances in the understanding and treatment of sepsis-induced immunosuppression.

Authors:  Fabienne Venet; Guillaume Monneret
Journal:  Nat Rev Nephrol       Date:  2017-12-11       Impact factor: 28.314

5.  STAT5 phosphorylation in T cell subsets from septic patients in response to recombinant human interleukin-7: a pilot study.

Authors:  Julie Demaret; Guillaume Dupont; Fabienne Venet; Arnaud Friggeri; Alain Lepape; Thomas Rimmelé; Jérôme Morel; Guillaume Monneret
Journal:  J Leukoc Biol       Date:  2015-02-17       Impact factor: 4.962

6.  IL-7 Restores T Lymphocyte Immunometabolic Failure in Septic Shock Patients through mTOR Activation.

Authors:  Fabienne Venet; Julie Demaret; Benjamin J Blaise; Christelle Rouget; Thibaut Girardot; Estellie Idealisoa; Thomas Rimmelé; François Mallet; Alain Lepape; Julien Textoris; Guillaume Monneret
Journal:  J Immunol       Date:  2017-07-19       Impact factor: 5.422

Review 7.  Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach.

Authors:  Richard S Hotchkiss; Guillaume Monneret; Didier Payen
Journal:  Lancet Infect Dis       Date:  2013-03       Impact factor: 25.071

8.  Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients.

Authors:  Caroline Guignant; Alain Lepape; Xin Huang; Hakim Kherouf; Laure Denis; Françoise Poitevin; Christophe Malcus; Aurélie Chéron; Bernard Allaouchiche; François Gueyffier; Alfred Ayala; Guillaume Monneret; Fabienne Venet
Journal:  Crit Care       Date:  2011-03-21       Impact factor: 9.097

  8 in total
  1 in total

1.  Intravenous Arginine Administration Benefits CD4+ T-Cell Homeostasis and Attenuates Liver Inflammation in Mice with Polymicrobial Sepsis.

Authors:  Chiu-Li Yeh; Sharon Angela Tanuseputero; Jin-Ming Wu; Yi-Ru Tseng; Po-Jen Yang; Po-Chu Lee; Sung-Ling Yeh; Ming-Tsan Lin
Journal:  Nutrients       Date:  2020-04-10       Impact factor: 5.717

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.